BioCentury
ARTICLE | Company News

GW gains on first sales figure for Epidiolex

February 27, 2019 7:53 PM UTC

GW Pharmaceuticals plc (NASDAQ:GWPH) added $21.10 (14%) to $173.99 on Wednesday after reporting that sales of Epidiolex cannabidiol reached $4.7 million in the two-month period since the marijuana-derived drug's launch on Nov. 1.

FDA approved Epidiolex in June to treat seizures associated with Lennox-Gastaut syndrome and Dravet syndrome in patients ages two and older. In September, the U.S. Drug Enforcement Agency rescheduled Epidiolex to schedule V from schedule I, clearing the drug for U.S. launch (see "FDA Approves GW’s Epidiolex, First Marijuana-Derived Drug")...

BCIQ Company Profiles

GW Pharmaceuticals plc